PL1663182T3 - Szybko rozpuszczalna formulacja cynakalcetu HCI - Google Patents

Szybko rozpuszczalna formulacja cynakalcetu HCI

Info

Publication number
PL1663182T3
PL1663182T3 PL04781429T PL04781429T PL1663182T3 PL 1663182 T3 PL1663182 T3 PL 1663182T3 PL 04781429 T PL04781429 T PL 04781429T PL 04781429 T PL04781429 T PL 04781429T PL 1663182 T3 PL1663182 T3 PL 1663182T3
Authority
PL
Poland
Prior art keywords
rapid dissolution
cinacalcet hcl
dissolution formulation
formulation
cinacalcet
Prior art date
Application number
PL04781429T
Other languages
English (en)
Other versions
PL1663182T5 (pl
Inventor
Francisco J Alvarez
Glen Gary Lawrence
Hung-Ren H Lin
Tzuchi R Ju
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34434844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1663182(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of PL1663182T3 publication Critical patent/PL1663182T3/pl
Publication of PL1663182T5 publication Critical patent/PL1663182T5/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL04781429T 2003-09-12 2004-09-10 Szybko rozpuszczalna formulacja cynakalcetu HCI PL1663182T5 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50221903P 2003-09-12 2003-09-12
EP04781429.8A EP1663182B2 (en) 2003-09-12 2004-09-10 RAPID DISSOLUTION FORMULATION OF CINACALCET HCl
PCT/US2004/026732 WO2005034928A1 (en) 2003-09-12 2004-09-10 Rapid dissolution formulation of a calcium receptor-active compound

Publications (2)

Publication Number Publication Date
PL1663182T3 true PL1663182T3 (pl) 2013-06-28
PL1663182T5 PL1663182T5 (pl) 2020-07-27

Family

ID=34434844

Family Applications (6)

Application Number Title Priority Date Filing Date
PL18175499T PL3395340T3 (pl) 2003-09-12 2004-09-10 Szybko rozpuszczająca się formulacja cynakalcetu HCl
PL14163366T PL2821067T3 (pl) 2003-09-12 2004-09-10 Szybko rozpuszczający się preparat cynakalcetu
PL18175497T PL3395339T3 (pl) 2003-09-12 2004-09-10 Szybko rozpuszczająca się formulacja cynakalcetu HCl
PL18175495T PL3395338T3 (pl) 2003-09-12 2004-09-10 Szybko rozpuszczająca się formulacja zawierająca cynakalcet HCl
PL04781429T PL1663182T5 (pl) 2003-09-12 2004-09-10 Szybko rozpuszczalna formulacja cynakalcetu HCI
PL17185704T PL3260117T3 (pl) 2003-09-12 2004-09-10 Szybko rozpuszczająca się formulacja zawierająca cynakalcet HCl

Family Applications Before (4)

Application Number Title Priority Date Filing Date
PL18175499T PL3395340T3 (pl) 2003-09-12 2004-09-10 Szybko rozpuszczająca się formulacja cynakalcetu HCl
PL14163366T PL2821067T3 (pl) 2003-09-12 2004-09-10 Szybko rozpuszczający się preparat cynakalcetu
PL18175497T PL3395339T3 (pl) 2003-09-12 2004-09-10 Szybko rozpuszczająca się formulacja cynakalcetu HCl
PL18175495T PL3395338T3 (pl) 2003-09-12 2004-09-10 Szybko rozpuszczająca się formulacja zawierająca cynakalcet HCl

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL17185704T PL3260117T3 (pl) 2003-09-12 2004-09-10 Szybko rozpuszczająca się formulacja zawierająca cynakalcet HCl

Country Status (30)

Country Link
US (7) US7829595B2 (pl)
EP (8) EP1663182B2 (pl)
JP (3) JP5026077B2 (pl)
KR (1) KR101332058B1 (pl)
CN (1) CN1946382B (pl)
AR (1) AR045637A1 (pl)
AU (1) AU2004279318C1 (pl)
BR (2) BRPI0414254B8 (pl)
CA (1) CA2536487C (pl)
CY (5) CY1119609T1 (pl)
DE (1) DE19164145T1 (pl)
DK (6) DK2821067T3 (pl)
EA (1) EA013425B1 (pl)
ES (7) ES2735216T3 (pl)
HR (1) HRP20130114T4 (pl)
HU (5) HUE045411T2 (pl)
IL (1) IL173737A (pl)
IS (1) IS3027B (pl)
MX (1) MXPA06002616A (pl)
MY (1) MY142046A (pl)
NO (1) NO335739B1 (pl)
NZ (1) NZ545498A (pl)
PL (6) PL3395340T3 (pl)
PT (6) PT2821067T (pl)
SG (1) SG146608A1 (pl)
SI (6) SI3260117T1 (pl)
TR (4) TR201910447T4 (pl)
TW (1) TWI344363B (pl)
WO (1) WO2005034928A1 (pl)
ZA (1) ZA200602710B (pl)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2821067T (pt) * 2003-09-12 2017-12-01 Amgen Inc Formulação de cinacalcet de dissolução rápida
RS56873B1 (sr) 2004-06-24 2018-04-30 Vertex Pharma Modulatori atp-vezujućih kasetnih transportera
JP4773436B2 (ja) * 2005-05-16 2011-09-14 テバ ファーマシューティカル インダストリーズ リミティド シナカルセト塩酸塩の調製方法
EP1883625A2 (en) * 2005-05-23 2008-02-06 Teva Pharmaceutical Industries Ltd Amorphous cinacalcet hydrochloride and preparation thereof
EP1805135A2 (en) * 2005-05-23 2007-07-11 Teva Pharmaceutical Industries Ltd. Purification of cinacalcet
DK2422783T3 (en) 2005-05-26 2015-05-11 Sumitomo Dainippon Pharma Co Ltd pharmaceutical composition
EP1937233B1 (en) * 2005-09-02 2013-01-09 Amgen Inc. Modulating intestinal fluid balance using calcimimetics
CA2625299A1 (en) * 2005-11-22 2007-05-31 Teva Pharmaceutical Industries Ltd. Crystal forms of cinacalcet hci and processes for their preparation
EP3219705B1 (en) 2005-12-28 2020-03-11 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of the amorphous form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US8426391B2 (en) 2006-02-03 2013-04-23 Proventiv Therapeutics, Llc Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3
JP5309014B2 (ja) * 2006-03-23 2013-10-09 アムジエン・インコーポレーテツド シナカルセットの多形体の製造および使用のための方法および組成物
EP1915335B1 (en) * 2006-04-27 2009-11-04 Teva Pharmaceutical Industries Ltd Process for the preparation of cinacalcet base
KR20080011320A (ko) * 2006-04-27 2008-02-01 테바 파마슈티컬 인더스트리즈 리미티드 시나칼셋 염기의 제조 방법
SI2679228T1 (en) 2006-06-21 2018-06-29 Opko Ireland Global Holdings, Ltd. THERAPY WITH THE USE OF VITAMIN D ADDITIONAL FIBER AND HORMON RESISTANCE OF VITAMIN D
EP2069285A1 (en) * 2006-06-27 2009-06-17 Sandoz AG Amorphous form of cinacalcet
JP2010501642A (ja) * 2006-09-01 2010-01-21 テバ ファーマシューティカル インダストリーズ リミティド カルシウム受容体−活性化合物の固体複合材料
WO2008064202A2 (en) * 2006-11-20 2008-05-29 Dr. Reddy's Labortories, Ltd. Modified-release formulations of calcium receptor-active compounds
WO2008063645A1 (en) * 2006-11-20 2008-05-29 Teva Pharmaceutical Industries Ltd. Process for preparing cinacalcet
TW201718635A (zh) 2007-03-06 2017-06-01 安美基公司 變異之活動素受體多肽及其用途
WO2008122010A1 (en) * 2007-04-02 2008-10-09 Concert Pharmaceuticals, Inc. Pharmaceutical calcimimetics
PT2148684E (pt) 2007-04-25 2013-04-19 Cytochroma Inc Método de tratamento para a insuficiência e deficiência de vitamina d
KR20190028822A (ko) 2007-04-25 2019-03-19 사이토크로마 인코포레이티드 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
ES2569483T3 (es) 2007-06-21 2016-05-11 Amgen Inc. Métodos para sintetizar cinacalcet y sales del mismo
US20090093652A1 (en) * 2007-08-16 2009-04-09 Michal Rafilovich Crystalline forms cinacalcet fumarate and cinacalcet succinate and processes for preparation thereof
US20110189241A1 (en) * 2008-05-05 2011-08-04 Medichem, S.A. Process For Controlling The Particle Size of A [3-(Trifluoromethyl)Phenyl]-1-Aminopropane Derivative
US20100074949A1 (en) * 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US20100256184A1 (en) * 2008-08-13 2010-10-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
EP2334284B1 (de) * 2008-09-25 2012-08-08 Ratiopharm GmbH Kompaktiertes cinacalcet
WO2010086129A1 (en) 2009-01-27 2010-08-05 Rathiopharm Gmbh Inclusion complex comprising cinacalcet and cyclodextrin
PT2408750E (pt) 2009-03-20 2015-10-15 Vertex Pharma Processo para a produção de modeladores do regulador de condutância transmembranar da fibrose cística
EP2435400A2 (en) 2009-05-27 2012-04-04 Leo Pharma A/S Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof
JP2012528086A (ja) 2009-05-27 2012-11-12 レオ ファーマ アクティーゼルスカブ 新規のカルシウム感知受容体調節化合物およびその医薬用途
EP2314286A1 (de) 2009-10-21 2011-04-27 Ratiopharm GmbH Schmelzgranuliertes Cinacalcet
RS60087B1 (sr) 2010-03-29 2020-05-29 Opko Ireland Global Holdings Ltd Postupci i kompozicije za snižavanje nivoa paratireoidnog hormona
WO2012021629A2 (en) 2010-08-11 2012-02-16 Philadelphia Health & Education Corporation Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease
EP2642980B8 (en) * 2010-11-23 2020-06-03 Amgen Inc. Pediatric formulation
US20130267516A1 (en) 2010-11-26 2013-10-10 Leo Pharma A/S Substituted cyclopentyl-azines as casr-active compounds
WO2012069420A2 (en) 2010-11-26 2012-05-31 Leo Pharma A/S Calcium-sensing receptor-active compounds
US20130245084A1 (en) 2010-11-26 2013-09-19 Leo Pharma A/S Calcium-sensing receptor-active compounds
RU2013128968A (ru) 2010-11-26 2015-01-10 Лео Фарма А/С Соединения, активные в отношении кальций-чувствительного рецептора
MX358358B (es) 2011-12-19 2018-08-15 Amgen Inc Polipeptidos de receptores de activina variantes y sus usos.
EP2804588B1 (en) 2012-01-17 2017-09-06 Zentiva Saglik Urunleri San. Ve Tic. A.S. Method for producing cinacalcet compositions for direct tableting
EP2819670A1 (en) 2012-02-27 2015-01-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administration thereof
CN102885792A (zh) * 2012-10-12 2013-01-23 华润赛科药业有限责任公司 盐酸西那卡塞的口服固体速释制剂
DK2730279T3 (en) 2012-11-09 2015-10-26 K H S Pharma Holding Gmbh CINACALCETFORMULERINGER immediate release
HK1216240A1 (zh) 2012-11-14 2016-10-28 W. R. Grace & Co.-Conn. 含有生物活性材料与无序无机氧化物的组合物
AU2013366640B2 (en) * 2012-12-21 2018-09-06 Synthon B.V. Tablet composition comprising cinacalcet hydrochloride
CN105431455A (zh) 2013-02-01 2016-03-23 圣塔玛丽亚生物疗法公司 抗激活素a化合物对受试者的施用
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
CA2915432C (en) * 2013-06-26 2019-03-05 Jubilant Life Sciences Limited Disintegrant free composition of cinacalcet
WO2015136329A1 (en) 2014-03-14 2015-09-17 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical composition of cinacalcet
WO2015150944A1 (en) 2014-03-29 2015-10-08 Wockhardt Limited Solid oral pharmaceutical compositions comprising cinacalcet or a salt thereof
US10220047B2 (en) * 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
US9701639B2 (en) 2014-10-07 2017-07-11 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
CN104721164B (zh) * 2015-03-25 2017-07-07 河北仁合益康药业有限公司 一种盐酸西那卡塞薄膜衣片组合物
SG11201808227YA (en) 2016-03-28 2018-10-30 Opko Ireland Global Holdings Limited Methods of vitamin d treatment
EP3437646A4 (en) 2016-03-31 2019-11-27 Intercept Pharmaceuticals, Inc. ORAL PREPARATION WITH EXTRAORDINARY ELABILITY
US11331283B2 (en) * 2017-08-16 2022-05-17 Unichem Laboratories Ltd Pharmaceutical compositions comprising cinacalcet hydrochloride and one or more binders
US20210030671A1 (en) 2018-03-30 2021-02-04 Ftf Pharma Private Limited Liquid dosage forms of cinacalcet or salt thereof
US10920483B2 (en) 2018-10-25 2021-02-16 Mark Mutchnik Window seal for preventing water penetration
RU2750761C2 (ru) * 2019-09-17 2021-07-02 Общество с ограниченной ответственностью "АМЕДАРТ" Ядро таблетки, содержащей цинакальцета гидрохлорид
KR20240031421A (ko) * 2020-02-29 2024-03-07 켐팜 인코포레이티드 메틸페니데이트-전구약물을 포함하는 조성물, 이를 제조 및 사용하는 방법
CN112546010A (zh) * 2020-12-02 2021-03-26 普莱赛思(天津)生命科技有限公司 一种肾病药物组合物及其制备方法

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4517179A (en) 1983-04-29 1985-05-14 Pennwalt Corporation Rapid dissolving, uniform drug compositions and their preparation
IL88150A0 (en) 1987-11-02 1989-06-30 Merck & Co Inc Pharmaceutical tablet compositions containing phthalizine acetic acid compounds
EP0357815A1 (de) 1988-09-06 1990-03-14 Siemens Aktiengesellschaft Schaltbare Konstantstromquelle mit I2L-Gattern
KR900701255A (ko) 1988-11-30 1990-12-01 스테이너 브이.캔스타드 서방성 딜티아젬 제제
NZ231897A (en) * 1988-12-30 1992-09-25 Monsanto Co Dry water-soluble granular composition comprising glyphosate and a liquid surfactant
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
US4931286A (en) 1989-04-19 1990-06-05 Aqualon Company High gloss cellulose tablet coating
DD299322A5 (de) * 1989-09-21 1992-04-09 Maschinenfabrik Rieter Ag,Ch Verfahren und vorrichtung zur feinreinigung von textilfasern
US5011068A (en) * 1989-12-05 1991-04-30 Progressive Tool & Industries Co. Automotive body framing system
US6001884A (en) 1991-08-23 1999-12-14 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6313146B1 (en) * 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
RU2147574C1 (ru) 1991-08-23 2000-04-20 Эн-Пи-Эс Фармасьютикалз, Инк. Арилалкиламины, композиции, способы лечения и диагностики, способы идентификации соединения
DK0724561T3 (da) 1991-08-23 2004-06-28 Nps Pharma Inc Calciumreceptoraktive arylalkylaminer
US6011068A (en) * 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6031003A (en) 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5162117A (en) 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
RU2146132C1 (ru) 1993-02-23 2000-03-10 Брихэм энд Уимен З Хоспитал, Инк. Фармацевтическая композиция, активная в отношении рецептора кальция, способ лечения пациента, способ анализа соединения оказывать влияние на активность рецептора неорганического иона, нуклеиновая кислота, кодирующая рецептор, рецептор кальция
US6210714B1 (en) * 1993-11-23 2001-04-03 Euro-Celtique S.A. Immediate release tablet cores of acetaminophen having sustained-release coating
NZ272608A (en) * 1994-07-22 2000-05-26 Lilly Co Eli Inhibiting bone loss by administering a bisphosphonate and a second compound selected from various compounds, including 2-phenyl-3-aroylbenzothienes; bisphosphonate combination salts
UA55374C2 (uk) 1994-10-21 2003-04-15 Нпс Фармасьютікалз, Інк Сполуки, що мають активність по відношенню до рецепторів кальцію
GB9424766D0 (en) 1994-12-07 1995-02-08 Wellcome Found Pharmaceutical composition
GB9501127D0 (en) 1995-01-20 1995-03-08 Wellcome Found Tablet
DE19530575A1 (de) 1995-08-19 1997-02-20 Gruenenthal Gmbh Schnell zerfallende Arzneiform von Tramadol oder einem Tramadolsalz
EP0907631B1 (en) * 1996-05-01 2003-06-18 Nps Pharmaceuticals, Inc. Inorganic ion receptor-active compounds
US5837292A (en) 1996-07-03 1998-11-17 Yamanouchi Europe B.V. Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug
WO1998001417A1 (en) 1996-07-08 1998-01-15 Kirin Beer Kabushiki Kaisha Calcium receptor-active compounds
DE19637082A1 (de) 1996-09-12 1998-03-19 Boehringer Mannheim Gmbh Schnellzerfallende Pellets
TW483881B (en) 1996-12-03 2002-04-21 Nps Pharma Inc Calcilytic compounds
IE970588A1 (en) * 1997-08-01 2000-08-23 Elan Corp Plc Controlled release pharmaceutical compositions containing tiagabine
WO1999009458A1 (de) 1997-08-13 1999-02-25 OCé PRINTING SYSTEMS GMBH Druck- oder kopiergerätesystem zum performanceangepassten erstellen einer vorgegebenen blattfolge von monochrom und/oder farbig bedruckten einzelblättern
NZ507271A (en) 1998-03-06 2003-03-28 Eurand Internat S Fast disintegrating tablets
US6525084B2 (en) 1998-07-23 2003-02-25 Novo Nordisk A/S Stable pharmaceutical formulation
AU760889B2 (en) * 1998-10-14 2003-05-22 Ortho-Mcneil Pharmaceutical, Inc. 1,2-disubstituted cyclopropanes
CZ304306B6 (cs) * 1998-11-23 2014-02-26 Monsanto Technology Llc Vysoce koncentrované vodné glyfosátové kompozice
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6447809B1 (en) * 1999-05-11 2002-09-10 Metagenics, Inc. Composition for promoting healthy bone structure
US6733780B1 (en) 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
FR2800735B1 (fr) 1999-11-09 2002-02-01 Centre Nat Rech Scient Nouvelles aralkyle-1,2-diamines possedant une activite calcimimetique et leur mode de preparation
PL355391A1 (pl) * 1999-12-22 2004-04-19 Pharmacia Corporation Kompozycja o przedłużonym uwalnianiu inhibitora cyklooksygenazy-2
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
AU5066101A (en) * 2000-04-13 2001-10-30 Synthon B.V. Modified release formulations containing a hypnotic agent
US6419954B1 (en) * 2000-05-19 2002-07-16 Yamanouchi Pharmaceutical Co., Ltd. Tablets and methods for modified release of hydrophilic and other active agents
FR2809396B1 (fr) 2000-05-24 2005-10-14 Centre Nat Rech Scient Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation
US6656492B2 (en) * 2000-06-30 2003-12-02 Yamanouchi Pharmaceutical Co., Ltd. Quick disintegrating tablet in buccal cavity and manufacturing method thereof
CA2423329A1 (en) 2000-09-22 2003-03-20 Takeda Chemical Industries, Ltd. Solid preparations
JP2002167327A (ja) * 2000-09-22 2002-06-11 Takeda Chem Ind Ltd 固形製剤
US7049283B2 (en) * 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
IN191028B (pl) * 2001-05-17 2003-09-13 Sun Pharmaceutical Ind Ltd
CA2448864C (en) 2001-06-22 2008-04-22 Pfizer Products Inc. Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug in a matrix and a solubility-enhancing polymer
EP1321142A1 (en) 2001-12-21 2003-06-25 Novartis AG Solid pharmaceutical composition for oral administration of Tegaserod
WO2003086343A2 (en) 2002-04-05 2003-10-23 Cadila Healthcare Limited Fast disintegrating oral dosage forms
US20050147670A1 (en) * 2002-05-29 2005-07-07 Impax Laboratories Inc. Oral disintegrating dosage forms
AU2003272767A1 (en) 2002-09-30 2004-04-23 Schering Corporation Use of tricyclic amides for the treatment of disorders of calcium homeostasis
GB0230015D0 (en) 2002-12-23 2003-01-29 Novartis Ag Organic compounds
PT2821067T (pt) 2003-09-12 2017-12-01 Amgen Inc Formulação de cinacalcet de dissolução rápida
EP1713489B1 (en) 2004-08-23 2011-01-19 Teva Pharmaceutical Industries Ltd Crystalline form of ibandronate sodium and processes for preparation thereof
NL1028867C2 (nl) 2005-04-26 2006-10-27 Xycarb Ceramics B V Inrichting voor het ondersteunen van een substraat alsmede een werkwijze voor het vervaardigen van een dergelijke inrichting.
US8922209B2 (en) 2008-03-11 2014-12-30 The University Of Western Ontario System and method for magnetic resonance imaging

Also Published As

Publication number Publication date
JP2015007089A (ja) 2015-01-15
TW200518743A (en) 2005-06-16
IL173737A0 (en) 2006-07-05
HUE035596T2 (en) 2018-05-28
CY1119609T1 (el) 2018-04-04
PT3260117T (pt) 2019-07-04
US7829595B2 (en) 2010-11-09
EP3395339B1 (en) 2019-04-17
BRPI0414254B8 (pt) 2021-05-25
IS8324A (is) 2006-02-23
HUE044822T2 (hu) 2019-11-28
DK1663182T4 (da) 2020-02-17
TWI344363B (en) 2011-07-01
PT2821067T (pt) 2017-12-01
SI3260117T1 (sl) 2019-08-30
PL3395339T3 (pl) 2019-09-30
MY142046A (en) 2010-08-30
ES2812198T1 (es) 2021-03-16
ES2737348T3 (es) 2020-01-13
PT3395339T (pt) 2019-07-15
PL1663182T5 (pl) 2020-07-27
WO2005034928A1 (en) 2005-04-21
CA2536487C (en) 2011-10-25
ZA200602710B (en) 2007-04-25
PL3395338T3 (pl) 2019-10-31
EP3395340B1 (en) 2019-04-17
TR201910180T4 (tr) 2019-07-22
EA200600566A1 (ru) 2006-08-25
EA013425B1 (ru) 2010-04-30
EP3395339B8 (en) 2019-12-11
PL3395340T3 (pl) 2019-10-31
JP5940120B2 (ja) 2016-06-29
US9375405B2 (en) 2016-06-28
EP2821067A1 (en) 2015-01-07
US20200222340A1 (en) 2020-07-16
CN1946382B (zh) 2010-12-08
EP1663182A1 (en) 2006-06-07
DK3260117T3 (da) 2019-07-01
DE19164145T1 (de) 2021-04-29
US20210052518A1 (en) 2021-02-25
CN1946382A (zh) 2007-04-11
BRPI0414254A (pt) 2006-11-07
ES2655435T3 (es) 2018-02-20
BR122018013029B1 (pt) 2022-04-12
US20110136915A1 (en) 2011-06-09
KR101332058B1 (ko) 2013-11-22
MXPA06002616A (es) 2006-06-05
EP3260117A1 (en) 2017-12-27
PL2821067T3 (pl) 2018-02-28
CY1121820T1 (el) 2020-07-31
ES2401769T5 (es) 2020-07-01
HUE045411T2 (hu) 2019-12-30
EP3260117B8 (en) 2019-11-27
ES2735216T3 (es) 2019-12-17
TR201909267T4 (tr) 2019-07-22
KR20070017460A (ko) 2007-02-12
AU2004279318B2 (en) 2010-02-25
US20180243238A1 (en) 2018-08-30
ES2401769T3 (es) 2013-04-24
DK3395339T3 (da) 2019-07-22
NO335739B1 (no) 2015-02-02
IS3027B (is) 2021-03-15
US20050147669A1 (en) 2005-07-07
CA2536487A1 (en) 2005-04-21
US20190117592A1 (en) 2019-04-25
PT1663182E (pt) 2013-03-14
SI1663182T1 (sl) 2013-05-31
HUE044279T2 (hu) 2019-10-28
AU2004279318A1 (en) 2005-04-21
DK3395338T3 (da) 2019-07-22
DK1663182T3 (da) 2013-04-15
CY1122259T1 (el) 2020-11-25
TR201910447T4 (tr) 2019-08-21
ES2735226T3 (es) 2019-12-17
PL3260117T3 (pl) 2019-10-31
EP2316442A1 (en) 2011-05-04
HRP20130114T4 (hr) 2019-12-27
HUE043958T2 (hu) 2019-09-30
IL173737A (en) 2012-04-30
EP3395338A1 (en) 2018-10-31
EP2821067B1 (en) 2017-10-25
PT3395340T (pt) 2019-07-15
AR045637A1 (es) 2005-11-02
CY1121812T1 (el) 2020-07-31
JP5026077B2 (ja) 2012-09-12
JP2012197280A (ja) 2012-10-18
TR201910177T4 (tr) 2019-08-21
EP3395339A1 (en) 2018-10-31
SI3395340T1 (sl) 2019-08-30
EP1663182B2 (en) 2019-11-20
EP3395340A1 (en) 2018-10-31
SI2821067T1 (en) 2018-03-30
PT3395338T (pt) 2019-07-23
AU2004279318C1 (en) 2020-06-25
DK3395340T3 (da) 2019-07-15
SG146608A1 (en) 2008-10-30
CY1121814T1 (el) 2020-07-31
JP2007505108A (ja) 2007-03-08
DK2821067T3 (en) 2017-12-04
HRP20130114T1 (xx) 2013-03-31
EP3395340B8 (en) 2019-12-11
NZ545498A (en) 2010-04-30
EP3578175B1 (en) 2022-11-30
EP1663182B1 (en) 2013-01-16
EP3578175A1 (en) 2019-12-11
US20160338975A1 (en) 2016-11-24
SI3395338T1 (sl) 2019-08-30
JP5849015B2 (ja) 2016-01-27
ES2734057T3 (es) 2019-12-04
SI3395339T1 (sl) 2019-08-30
SI1663182T2 (sl) 2020-02-28
EP3260117B1 (en) 2019-04-17
NO20061640L (no) 2006-06-12
EP3395338B1 (en) 2019-05-01
BRPI0414254B1 (pt) 2021-03-02

Similar Documents

Publication Publication Date Title
HUE044822T2 (hu) Cinakalcet HCl gyors feloldódású készítménye
EP1684689A4 (en) VENLAFAXINE PREPARATION WITH PROLONGED RELEASE
GB0323908D0 (en) Pharmaceutical foam formulation
IL176248A0 (en) N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof
EG24479A (en) Modified release pharmaceutical formulation
GB0318448D0 (en) Formulation
GB0316206D0 (en) Pharmaceutical formulation
IL165069A0 (en) Immediate release pharmaceutical formulation
IL164077A0 (en) Sustained release formulation of tramadol
GB0312195D0 (en) Formulation
GB0320522D0 (en) Formulation
GB0303876D0 (en) Formulation
GB0318663D0 (en) Rolling formulation
GB0310881D0 (en) Pharmaceutical formulation
IL159780A0 (en) Extended release venlafaxine tablet formulation
GB0308978D0 (en) Formulation
ZA200510326B (en) Dimeticone-containing sustaned formulation
GB0316538D0 (en) Formulation
GB0302435D0 (en) Pharmaceutical formulation